Amneal Pharmaceuticals, Inc.
US ˙ NasdaqGS ˙ US03168L1052

Introduction

This page provides a comprehensive analysis of the known insider trading history of Chintu Patel. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Chintu Patel has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:AMRX / Amneal Pharmaceuticals, Inc. Co-CEO, Director 864,033
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Chintu Patel. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases AMRX / Amneal Pharmaceuticals, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in AMRX / Amneal Pharmaceuticals, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2020-03-10 AMRX Patel Chintu 100,000 3.0900 100,000 3.0900 309,000 364 5.98 289,000 93.53
2020-03-04 AMRX Patel Chintu 58,765 3.9700 58,765 3.9700 233,297
2020-03-03 AMRX Patel Chintu 156,539 3.8800 156,539 3.8800 607,371
2020-03-02 AMRX Patel Chintu 34,696 3.8700 34,696 3.8700 134,274

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

AMRX / Amneal Pharmaceuticals, Inc. Insider Trades
Insider Sales AMRX / Amneal Pharmaceuticals, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in AMRX / Amneal Pharmaceuticals, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

AMRX / Amneal Pharmaceuticals, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Chintu Patel as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-03-05 2025-03-04 4 AMRX Amneal Pharmaceuticals, Inc.
Class A Common Stock
F - Taxes -46,528 864,033 -5.11 8.84 -411,308 7,638,052
2025-03-05 2025-03-04 4 AMRX Amneal Pharmaceuticals, Inc.
Class A Common Stock
M - Exercise 92,592 910,561 11.32
2025-03-05 2025-03-03 4 AMRX Amneal Pharmaceuticals, Inc.
Class A Common Stock
F - Taxes -274,307 817,969 -25.11 8.76 -2,402,929 7,165,408
2025-03-05 2025-03-03 4 AMRX Amneal Pharmaceuticals, Inc.
Class A Common Stock
M - Exercise 579,710 1,092,276 113.10
2023-11-08 2023-11-07 4 AMRX Amneal Pharmaceuticals, Inc.
Class A Common Stock
J - Other 24,753,252 24,753,252
2022-03-03 2022-03-03 4 AMRX Amneal Pharmaceuticals, Inc.
Performance-Based Restricted Stock Units
A - Award 1,159,420 1,159,420
2021-12-17 2021-12-16 4 AMRX Amneal Pharmaceuticals, Inc.
Class A Common Stock
P - Purchase 50,000 512,566 10.81 4.25 212,500 2,178,406
2021-12-17 2021-12-15 4 AMRX Amneal Pharmaceuticals, Inc.
Class A Common Stock
P - Purchase 100,000 462,566 27.58 4.13 413,000 1,910,398
2021-03-03 2021-03-01 4 AMRX Amneal Pharmaceuticals, Inc.
Performance-Based Restricted Stock Units
A - Award 926,640 926,640
2020-05-08 2020-05-07 4 AMRX Amneal Pharmaceuticals, Inc.
Restricted Stock Units
M - Exercise -6,459 0 -100.00
2020-05-08 2020-05-07 4 AMRX Amneal Pharmaceuticals, Inc.
Class A Common Stock
M - Exercise 6,459 362,566 1.81
2020-03-11 2020-03-10 4 AMRX Amneal Pharmaceuticals, Inc.
Class A Common Stock
P - Purchase 100,000 356,107 39.05 3.09 309,000 1,100,371
2020-03-10 2020-03-04 4 AMRX Amneal Pharmaceuticals, Inc.
Class A Common Stock
P - Purchase 58,765 256,107 29.78 3.97 233,297 1,016,745
2020-03-10 2020-03-03 4 AMRX Amneal Pharmaceuticals, Inc.
Class A Common Stock
P - Purchase 156,539 197,342 383.65 3.88 607,371 765,687
2020-03-10 2020-03-02 4 AMRX Amneal Pharmaceuticals, Inc.
Class A Common Stock
P - Purchase 34,696 40,803 568.13 3.87 134,274 157,908
2020-03-02 2020-02-27 4 AMRX Amneal Pharmaceuticals, Inc.
Performance-Based Restricted Stock Units
A - Award 1,266,490 1,266,490
2019-05-08 2019-05-08 4 AMRX Amneal Pharmaceuticals, Inc.
Restricted Stock Units
M - Exercise -6,107 0 -100.00
2019-05-08 2019-05-08 4 AMRX Amneal Pharmaceuticals, Inc.
Class A Common Stock
M - Exercise 6,107 6,107
2019-05-08 2019-05-06 4 AMRX Amneal Pharmaceuticals, Inc.
Restricted Stock Units
A - Award 6,459 6,459
2019-05-08 2019-05-06 4 AMRX Amneal Pharmaceuticals, Inc.
Stock Option
A - Award 28,044 28,044
2018-07-09 2018-07-05 4 AMRX Amneal Pharmaceuticals, Inc.
Common Units
J - Other 24,753,252 24,753,252
2018-07-09 2018-07-05 4 AMRX Amneal Pharmaceuticals, Inc.
Class B Common Stock
J - Other 24,753,252 24,753,252
2018-05-09 2018-05-07 4 AMRX Amneal Pharmaceuticals, Inc.
Restricted Stock Units
A - Award 6,107 6,107
2018-05-09 2018-05-07 4 AMRX Amneal Pharmaceuticals, Inc.
Stock Option
A - Award 24,977 24,977
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)